Navigation Links
Drug-eluting stents confirmed safe, effective for long-term use
Date:8/18/2010

Researchers at the Rabin Medical Center in Israel have determined that the use of drug-eluting stents (DES) improves the long-term clinical outcome for patients undergoing percutaneous coronary intervention (PCI), commonly known as angioplasty. Results of this study appear in the September issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

PCI is used to treat coronary artery disease and is one of the most common medical procedures. Expert reports indicate there were 1,313,000 PCI/angioplasties conducted in the U.S. in 2006. Randomized clinical trials indicate DES decreases in-stent restenosis and the frequency of repeat revascularization procedures in patients undergoing PCI, yet questions remain about the long-term safety and/or effectiveness of DES in routine clinical practice among large unselected population cohorts.

In the current study, the Israeli team examined the benefits and long-term risks of DES by evaluating the established pattern of DES versus bare-metal stent (BMS) use in routine clinical practice in Israel. Israeli guidelines established by the Israel Heart Society and the Ministry of Health require DES be used preferentially in proximal main vessels, diabetic patients, and in long lesions to reduce restenosis.

The study population comprised all consecutive cases of PCI with stent implantation over a 4-year period at the two hospitals of the Rabin Medical Center. The entire cohort consisted of 6,583 patients, 2,633 (40%) patients with a DES and 3,950 (60%) patients with BMS. The minimal follow-up time was 6 months, and the maximal follow-up time was 5.2 years, with a mean follow-up time of 3 years. Propensity score matching and stratified analysis was used to define the clinical effectiveness and safety profile of DES versus BMS among ''all comers'' patients treated at the Center, using carefully validated long-term follow-up mortality and morbidity endpoints. Propensity score matching was performed using an algorithm to match each DES patient with a BMS patient with the closest propensity score. Each pair was used once and unpaired cases were not used in further analysis. The propensity matched group consisted of 4,398 patients (2,199 matched pairs).

The usage pattern set by the Israel Ministry of Health directives was generally followed, with 40% of the procedures including a DES. Patients who received DES were slightly younger and more likely to be diabetic. Their index intervention was less likely to be emergent. The main features associated with the DES group were the use of longer or more stents per lesion, treatment of more territories, more sites per territory and of more proximal main vessels. Of the patients with DES, 66% had a DES only, whereas 34% had a combination of a DES and a BMS.

Results show that use of DES compared with BMS reduced the occurrence of myocardial infarction (MI) (5.17% vs. 5.83%) and the need for clinically driven target vessel revascularization (TVR) (9.76% vs. 12.28%). Mortality was significantly lower in the DES group, showing a persistent benefit of DES over time (23.38% for DES vs. 26.07% in BMS).

Study leader Dr. Tamir Bental concludes, "The main effect of DES is reduced restenosis, which is evident in our analysis. This outcome was sustained over time and could certainly be a major factor contributing to the survival benefit of DES. We suggest that a possible additional factor contributing to our results could be the pattern of use of the DES in our practicetreatment of more territories and more sites per territory, probably leading to a more complete revascularization. Another salient feature was the preferential treatment of more proximal main vessel. Therefore, treatment of proximal lesions could contribute to a better outcome."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery
2. Stents May Be Effective Weapon Against Stroke
3. Stents as good as surgery for clogged carotid arteries
4. Many Dont Take Blood Thinner After Getting Stents
5. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
6. Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
7. Vitamin D deficiency confirmed as common across a range of rheumatic conditions
8. The protective brain hypothesis is confirmed
9. Thrush Sufferers Seek Out Safe, Natural Remedies for Thrush, Driving a 237% Increase in Sales for "The 3 Day Thrush Cure"
10. Find Safe, Affordable Prescription Alternatives at SplitMed.com - New Site for Discount Prescription Drugs
11. buySAFE, Inc. Releases a Breakthrough White Paper that is a Must Read for Every Internet Retailer Interested in Increasing Website Conversion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology: